Tien Liang BioTech Co., Ltd. (TPEX:4127)
Taiwan · Delayed Price · Currency is TWD 35.55
-0.05 (-0.14%)
At close: Mar 26, 2026
Tien Liang BioTech Revenue
In the year 2025, Tien Liang BioTech had annual revenue of 511.79M TWD with 32.86% growth. Tien Liang BioTech had revenue of 131.65M in the quarter ending December 31, 2025, with 51.53% growth.
Revenue
511.79M
Revenue Growth
+32.86%
P/S Ratio
3.18
Revenue / Employee
5.82M
Employees
88
Market Cap
1.63B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 511.79M | 126.59M | 32.86% |
| Dec 31, 2024 | 385.21M | -74.79M | -16.26% |
| Dec 31, 2023 | 459.99M | -68.53M | -12.97% |
| Dec 31, 2022 | 528.52M | -42.79M | -7.49% |
| Dec 31, 2021 | 571.32M | 140.23M | 32.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TSH Biopharm Corporation | 1.34B |
| Excelsior Biopharma | 898.26M |
| Anxo Pharmaceutical | 883.22M |
| Allied Biotech | 849.51M |
| Winston Medical Supply | 724.35M |
| DV Biomed | 712.61M |
| GeneFerm Biotechnology | 677.10M |
| Johnson Chemical Pharmaceutical Works | 569.77M |